Source comparison
Peptides vs HGH Injections: Clinical Comparison
Mechanism Stimulates endogenous GH release via ghrelin, GHRH, or GHRP receptors. Preserves pituitary feedback regulation Replaces endogenous GH with synthetic somatotropin. Shuts down natural production within 4–8 weeks Peptides work with your axis; HGH replac
This comparison does not assign a generated winner or score.
- Mechanism
- Stimulates endogenous GH release via ghrelin, GHRH, or GHRP receptors. Preserves pituitary feedback regulation
- Replaces endogenous GH with synthetic somatotropin. Shuts down natural production within 4–8 weeks
- Peptides work with your axis; HGH replaces it. Choose based on whether you need amplification or replacement.
- Monthly Cost
- $120–$400 (oral MK-677 or injectable GHRP stacks)
- $800–$3,000 (2–10 IU daily, pharmaceutical-grade)
- Peptides cost 60–85% less at equivalent subjective efficacy for recovery and body composition.
- Legal Classification
- Research compounds (not FDA-approved for human use, legal to purchase for research)
- Schedule III controlled substance (requires prescription, DEA-tracked)
- HGH carries federal prosecution risk if obtained without valid Rx; peptides exist in regulatory gray zone.
- IGF-1 Elevation
- 30–60% above baseline (dose-dependent, pulsatile)
- 200–400% above baseline (sustained, dose-dependent)
- HGH produces far higher IGF-1 levels. Also higher metabolic and endocrine risk.
- Axis Suppression
- None. Endogenous GH production continues normally
- Complete. Natural GH secretion ceases, recovery takes 6–12 months post-cessation
- Stopping peptides has no rebound deficiency; stopping HGH does.
- Insulin Sensitivity Impact
- Minimal (5–8 mg/dL fasting glucose increase)
- Significant (10–20 mg/dL increase, 0.3% HbA1c rise over 12 months)
- Chronic HGH use is a prediabetes risk; peptides are not.